HarborOne Bancorp Inc Stock News

Analysts expect HarborOne Bancorp Inc (NASDAQ:HONE) to post sales of $45.35 million for the current fiscal quarter, according to Zacks Investment Research. Two analysts have issued estimates for Harbo

Medical stocks have struggled this year. But the best performing among them include medical technology companies that tend to have high Composite Ratings, a key metric measuring growth.

National Vision (EYE) continues to register strong segmental performances.

First Trust Advisors LP trimmed its position in shares of HarborOne Bancorp Inc (NASDAQ:HONE) by 4.2% during the fourth quarter, according to the company in its most recent filing with the Securities

Investors continue to be optimistic about STERIS (STE) on its strong segmental performance in Q3.

STERIS (STE) is optimistic about maintaining growth momentum on broader product and service portfolio along with several tuck-in acquisitions.

STERIS (STE) growing steadily on favorable underlying market trends, along with new product and service offerings.

Jim Blake became the CEO of HarborOne Bancorp, Inc. (NASDAQ:HONE) in 2016. This analysis aims first to contrast CEO...

HarborOne Bancorp (NASDAQ:HONE) was upgraded by stock analysts at BidaskClub from a “strong sell” rating to a “sell” rating in a research note issued to investors on Tuesday, BidAskClub report

I guess my discussions of purpose-driven banking are growing. Maybe I just picked up the vibe or created it, but more and more I’m seeing bank CEO’s talking about purpose. Tom Blomfield, CEO and c

Shares of HarborOne Bancorp Inc (NASDAQ:HONE) have received a consensus recommendation of “Hold” from the six ratings firms that are currently covering the company, MarketBeat Ratings reports. Two

Zacks.com featured highlights include: Farmers National, Independent Bank, First Financial Bankshares, HarborOne and Cue Biopharma

Increased analyst coverage over the last few weeks might lead to solid price appreciation for these stocks.

Increased analyst coverage over the last few weeks might lead to solid price appreciation for these stocks.

Steris (STE) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.